Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Twelve hospitals across India will be part of the network which will support the trial in India
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
Experts’ conclave to pave holistic approach to cancer management
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Having a healthy gut is key as it permits the body to build a stronger immune system
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
Subscribe To Our Newsletter & Stay Updated
